Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy TrialVida Terzić, Kévin Bouiller, Aline Dechanet et al.|Clinical Infectious Diseases|2024Cited by 14
Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label TrialFlorence Ader, Joy Mootien, Maude Bouscambert‐Duchamp et al.|SSRN Electronic Journal|2021Cited by 3
Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trialFlorence Ader, Joy Mootien, Maude Bouscambert-Duchamp et al.|medRxiv|2022Cited by 2
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2022Cited by 1
Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label TrialFlorence Ader, Joy Mootien, Maude Bouscambert‐Duchamp et al.|SSRN Electronic Journal|2021Cited by 0